Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBT: 2019-2024

Historic EBT for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$86.6 million.

  • Foghorn Therapeutics' EBT rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 15.98%. This contributed to the annual value of -$86.6 million for FY2024, which is 8.05% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported EBT of -$86.6 million as of FY2024, which was up 8.05% from -$94.2 million recorded in FY2023.
  • Foghorn Therapeutics' EBT's 5-year high stood at -$69.5 million during FY2020, with a 5-year trough of -$108.9 million in FY2022.
  • Over the past 3 years, Foghorn Therapeutics' median EBT value was -$94.2 million (recorded in 2023), while the average stood at -$96.6 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 47.58% in 2021, then increased by 13.48% in 2023.
  • Foghorn Therapeutics' EBT (Yearly) stood at -$69.5 million in 2020, then slumped by 47.58% to -$102.6 million in 2021, then fell by 6.14% to -$108.9 million in 2022, then rose by 13.48% to -$94.2 million in 2023, then increased by 8.05% to -$86.6 million in 2024.